美股新聞 標題聯播 · 近 24 小時 294 則 · 33 個來源 · 最新 9/20 03:26
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · VTRS近 30 天 12 則 · 第 1 / 1 頁
- 3 US Stocks That Could Gain If Buyers Shift Away From India
- Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation
- Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
- 3 Healthcare Stocks That Fall Short
- Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
- Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
- 3 Cash-Producing Stocks That Concern Us
- Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?
- Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
- 3 Generic Drug Stocks to Watch Amid Improving Industry Trends
- The Real Engine That Could Power Tesla Stock Higher
- Dell Stock's Massive Guidance Raise Has A Catch
- Viatris' China Policy Concerns Overstated, UBS Says
- 3 S&P 500 Stocks We Keep Off Our Radar
- 3 Stocks Under $50 We’re Skeptical Of
- 5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call
- Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
- Viatris (VTRS) Q2 2026 Earnings Call Transcript
- Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。